CGEM - NASDAQ
Cullinan Therapeutics, Inc.
$15.21
-0.85%Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
At a Glance
Live SnapshotCullinan Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cullinan Therapeutics, Inc. Cash Flow Statement
CGEM • NASDAQ
| Cullinan Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||
-219.9M | -167.6M | -153.2M | 109.2M | -67.5M | -51.8M | -21.7M | -14.2M | |
311K | 306K | 310K | 93K | 53K | 62K | 70K | 43K | |
0.0 | 0.0 | 0.0 | 0.0 | 3.1M | 0.0 | -4K | 0.0 | |
36M | 37.8M | 30.4M | 28M | 24.4M | 0.0 | 17K | 0.0 | |
-6.3M | -15.5M | -11.5M | -275.1M | 67K | 15.1M | 539K | 252K | |
(0.0) | (0.0) | (0.0) | (37.8M) | (0.0) | (0.0) | (0.0) | (0.0) | |
14.1M | -389K | -339K | 11.2M | -3.5M | 6.9M | 135K | 345K | |
-175.8M | -145.3M | -134.3M | -126.7M | -43.4M | -29.8M | -20.9M | -13.5M | |
INVESTING ACTIVITIES | ||||||||
-49K | (0.0) | -208K | -1.1M | -589.2K | -10K | -20K | -261K | |
(0.0) | (0.0) | -36K | (275M) | (923K) | (1.5M) | (0.0) | (0.0) | |
-236.5M | -721.1M | -373.4M | -377.9M | -525.8M | -69.8M | -35.4M | (0.0) | |
416.6M | 584.8M | 409.4M | 352.9M | 192M | 62.9M | 0.0 | 0.0 | |
0.0 | 0.0 | 36K | 91K | -333.8K | 0.0 | 0.0 | 0.0 | |
(180M) | -136.3M | (35.8M) | (249M) | -333.8M | -5.4M | -35.4M | -261K | |
FINANCING ACTIVITIES | ||||||||
1.1M | 262.7M | 38.4M | 8.4M | 267.3M | 140.1M | 0.0 | 1K | |
0.0 | 0.0 | 1.8M | -2.2M | 0.0 | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -378K | (0.0) | |
0.0 | 3.5M | 538K | -32.1M | 1.5M | 0.0 | 1.8M | -9K | |
1.1M | 266.2M | 40.8M | -25.9M | 268.8M | 140.1M | 85.7M | -29K | |
CASH FLOW SUMMARY | ||||||||
5.3M | -15.4M | -57.7M | 96.4M | -108.4M | 104.9M | 29.4M | -13.8M | |
83M | 98.4M | 156.2M | 59.8M | 168.2M | 63.3M | 33.8M | 47.7M | |
88.3M | 83M | 98.4M | 156.2M | 59.8M | 168.2M | 63.3M | 33.8M | |
-175.8M | -145.3M | -134.5M | -127.8M | -44M | -29.8M | -20.9M | -13.8M |
SEC Filings
CGEM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 18, 2026 | May 18, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | April 27, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 10, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 08, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 08, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 21, 2025 | November 18, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your CGEM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.